I.

1. Certolizumab (Cimzia®) – Production information, UCB, Dec 2013.

II.


[29] Japan College of Rheumatology, "Guidelines for the Use of Anti-TNF Drugs in Rheumatoid Arthritis (RA)," 2014.


[31] X. Li, M. A. Gignac and A. H. Anis, "The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work.," Medical Care, vol. 44, no. 4, pp. 304-10, 2006.


[93] Cimzia Summary of Product Characteristics

III.

1. Summary of Product Characteristic of Cimzia


33. Strand V, et al. "Rapid and sustained improvement in health-related quality of life, fatigue, and other patient-reported outcomes in RA patients treated with CZP plus MTX over 1 year: results from the RAPID 1


41. SMC, “Certolizumab Pegol in Rheumatoid Arthritis”, Published 11 October 2010.
